文献速递妇科

分子分型改善子宫内膜癌的术前风险评估

Molecular classification improves preoperative risk assessment of endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2024-07-16

这项回顾性单中心观察性研究纳入1994年12月至2022年5月初次手术治疗的子宫内膜腺癌患者658例,评估分子分型单独及联合术前临床数据预测宫外病变的性能。p53abn亚型与宫外扩散和淋巴结受累增加相关,多因素分析中仅p53abn亚型和影像学怀疑宫外病变独立预测术后宫外病变。结论认为分子分型在术前活检中预测晚期疾病比组织学类型或分级更准确。

要点

  • p53abn肿瘤宫外扩散率34.1%、淋巴结受累率30.1%(p < .001)。
  • 多因素分析中p53abn亚型aOR=16.0(95%CI 1.5-165.1)独立预测宫外病变。
  • 影像学怀疑宫外病变aOR=24.2(95%CI 12.2-48.2)独立预测宫外病变。

核心结论

  • 子宫内膜癌分子分型在术前活检中预测晚期疾病比组织学类型或分级更准确,与影像学检查共同构成最可靠的术前信息。
  • 本研究为术前利用分子信息定制手术治疗提供了初步框架。

研究设计与样本

  • 回顾性单中心观察性研究,纳入1994年12月至2022年5月初次手术治疗的子宫内膜腺癌患者658例。
  • 分子分型采用p53、MLH1、PMS2、MSH2和MSH6免疫组化及POLE基因6个最常见突变的KASP基因分型。
  • 采用逻辑回归、回归树和随机森林分类技术(CART)进行分析。

主要发现

  • 658例中POLEmut 47例(7.1%)、MMRd 234例(35.6%)、p53abn 95例(14.4%)、NSMP 282例(42.8%)。
  • 初次手术后诊断为晚期(III-IV期FIGO 2009)者占11.7%。
  • p53abn肿瘤宫外扩散率34.1%、淋巴结受累率30.1%(p < .001)。
  • 多因素分析中仅p53abn亚型(aOR=16.0,95%CI 1.5-165.1)和影像学怀疑宫外病变(aOR=24.2,95%CI 12.2-48.2)独立预测初次手术后宫外病变。
  • 术前影像学评估为子宫局限性疾病者中,影像学深肌层浸润和宫颈受累及p53abn分子亚型是识别分期手术后隐匿性宫外病变高危患者的最佳变量。

临床怎么用

  • 作者认为分子分型在术前活检中预测晚期疾病比组织学类型或分级更准确,与影像学检查共同构成最可靠的术前信息。
  • 作者指出本研究为术前利用分子信息定制手术治疗提供了初步框架。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to evaluate the performance of endometrial cancer (EC) molecular classification in predicting extrauterine disease after primary surgery alone and in combination with other clinical data available in preoperative setting. METHODS: Retrospective single-center observational study including patients with endometrial adenocarcinoma treated with primary surgery between December 1994 and May 2022. Molecular profiling was performed using immunohistochemistry of p53, MLH1, PMS2, MSH2 and MSH6; and KASP genotyping of the 6 most common mutations of POLE gene. Clinical, pathological and imaging information was reviewed. Logistic regression, regression trees and random forest classification techniques (CART) were performed. RESULTS: We enrolled 658 patients, 47 with POLEmut (7.1%), 234 with MMRd (35.6%), 95 with p53abn (14.4%) and 282 with NSMP (42.8%) tumors. Advanced stage after primary surgery (III-IV FIGO 2009) was diagnosed in 11.7% of patients, p53abn tumors showed increased extrauterine spread (34.1%) and nodal involvement (30.1%) (p < .001). In multivariate analysis, only p53abn subgroup (aOR = 16.0, CI95% = 1.5-165.1) and radiological suspicion of extrauterine disease (aOR = 24.2, CI95% = 12.2-48.2) independently predicted the finding of extrauterine disease after primary surgery. In patients with preoperative uterine-confined disease, deep myometrial and cervical involvement in radiological assessment and p53abn molecular subtype were the best variables to identify patients at-risk of occult extrauterine disease after the staging surgery. CONCLUSION: EC molecular classification is more accurate than histotype or grade in preoperative biopsy to predict advanced disease, and together with imaging tests are the most reliable preoperative information. This work provides an initial framework for using molecular information preoperatively to tailor surgical treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cabrera S, Bebia V, López-Gil C, et al. Molecular classification improves preoperative risk assessment of endometrial cancer. Gynecol Oncol. 2024. PMID: 39018900. doi:10.1016/j.ygyno.2024.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。